Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription

Articles published in J Neurol

Retrieve available abstracts of 300 articles:
HTML format

Single Articles

    July 2022
  1. MERGENTHALER P, Stetefeld HR, Dohmen C, Kohler S, et al
    Seronegative myasthenic crisis: a multicenter analysis.
    J Neurol. 2022;269:3904-3911.
    PubMed     Abstract available

  2. ALCALA C, Cubas L, Carratala S, Gascon F, et al
    NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
    J Neurol. 2022;269:3495-3500.
    PubMed     Abstract available

    June 2022
  3. LEGUY S, Lefort M, Lescot L, Michaud A, et al
    COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
    J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
    PubMed     Abstract available

  4. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
    Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
    J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
    PubMed     Abstract available

  5. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    PubMed     Abstract available

  6. ARINO H, Heartshorne R, Michael BD, Nicholson TR, et al
    Neuroimmune disorders in COVID-19.
    J Neurol. 2022;269:2827-2839.
    PubMed     Abstract available

  7. YOGANATHAN K, Stevenson A, Tahir A, Sadler R, et al
    Bedside and laboratory diagnostic testing in myasthenia.
    J Neurol. 2022;269:3372-3384.
    PubMed     Abstract available

  8. LAMBERT N, Lutteri L, Tshibanda L, Bianchi E, et al
    Anti-SOX1 antibody-associated acute hemorrhagic leukoencephalitis.
    J Neurol. 2022;269:3359-3362.

  9. JENTZER A, Carra-Dalliere C, Lozano C, Riviere S, et al
    Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.
    J Neurol. 2022;269:2850-2853.

  10. AYVACIOGLU CAGAN C, Temucin CM, Arslan D, Gocmen R, et al
    Isolated spinal cord granulomatous angiitis: a case report and review of the literature.
    J Neurol. 2022;269:3175-3179.
    PubMed     Abstract available

  11. VAN ROSMALEN MHJ, Froeling M, Mandija S, Hendrikse J, et al
    MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.
    J Neurol. 2022;269:3159-3166.
    PubMed     Abstract available

  12. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    J Neurol. 2022;269:3276-3285.
    PubMed     Abstract available

  13. AKAISHI T, Misu T, Fujihara K, Takahashi T, et al
    Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    J Neurol. 2022;269:3136-3146.
    PubMed     Abstract available

  14. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
    J Neurol. 2022;269:3129-3135.
    PubMed     Abstract available

  15. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    PubMed     Abstract available

    May 2022
  16. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.

  17. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    PubMed     Abstract available

  18. JARIUS S, Komorowski L, Regula JU, Haas J, et al
    Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
    J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
    PubMed     Abstract available

  19. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.

  20. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
    PubMed     Abstract available

  21. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
    Patients with multiple sclerosis: a burden and cost of illness study.
    J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
    PubMed     Abstract available

  22. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
    PubMed     Abstract available

  23. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
    Age-specific effects of childhood body mass index on multiple sclerosis risk.
    J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
    PubMed     Abstract available

  24. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
    Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
    J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
    PubMed     Abstract available

  25. GIANNOCCARO MP, Vacchiano V, Leone M, Camilli F, et al
    Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11142.
    PubMed     Abstract available

  26. SANSONE G, Bonifati DM
    Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11140.
    PubMed     Abstract available

  27. KIM H, Fraser S
    Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
    J Neurol. 2022;269:2378-2402.
    PubMed     Abstract available

  28. GELIBTER S, Bellavia G, Arbasino C, Arno N, et al
    Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19.
    J Neurol. 2022;269:2293-2300.
    PubMed     Abstract available

  29. WEISS D, Cantre D, Zettl UK, Storch A, et al
    Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab.
    J Neurol. 2022;269:2778-2780.

  30. HIROSE S, Hara M, Kamei S, Dalmau J, et al
    Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:2486-2492.
    PubMed     Abstract available

    April 2022
  31. HVID LG, Stenager E, Dalgas U
    Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
    J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
    PubMed     Abstract available

  32. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
    Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
    PubMed     Abstract available

  33. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
    Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
    J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
    PubMed     Abstract available

  34. ZHANG Y, Yin H, Zhang D, Xu Y, et al
    Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
    PubMed     Abstract available

  35. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
    PubMed     Abstract available

  36. STORELLI L, Pagani E, Meani A, Preziosa P, et al
    Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
    PubMed     Abstract available

  37. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
    Time course of lesion-induced atrophy in multiple sclerosis.
    J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
    PubMed     Abstract available

  38. MOOG TM, McCreary M, Wilson A, Stanley T, et al
    Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
    J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
    PubMed     Abstract available

  39. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
    Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.

  40. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
    Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
    J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
    PubMed     Abstract available

  41. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
    J Neurol. 2022;269:1758-1763.
    PubMed     Abstract available

  42. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
    Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
    J Neurol. 2022;269:2073-2079.
    PubMed     Abstract available

  43. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
    Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
    J Neurol. 2022;269:1786-1801.
    PubMed     Abstract available

  44. MASUDA H, Mori M, Yokouchi H, Uzawa A, et al
    Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
    J Neurol. 2022;269:1996-2003.
    PubMed     Abstract available

    March 2022
  45. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
    Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.

  46. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
    Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.

  47. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
    MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
    J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
    PubMed     Abstract available

  48. ALLMAN M, Tallantyre E, Robertson NP
    Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.

  49. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
    The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
    J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
    PubMed     Abstract available

  50. DU Y, Li C, Hao YF, Zhao C, et al
    Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11048.
    PubMed     Abstract available

  51. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
    Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
    PubMed     Abstract available

  52. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
    PubMed     Abstract available

  53. KUBICKI K, Grzybowski A
    Pioneers in neurology: Charles Miller Fisher (1913-2012).
    J Neurol. 2022;269:1727-1729.

  54. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
    Natalizumab-induced pneumonitis.
    J Neurol. 2022;269:1688-1690.

  55. KHAN E, Shrestha AK, Colantonio MA, Liberio RN, et al
    Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.
    J Neurol. 2022;269:1121-1132.
    PubMed     Abstract available

  56. WANG Y, Wang Y, Huo L, Li Q, et al
    SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature.
    J Neurol. 2022;269:1071-1092.
    PubMed     Abstract available

  57. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
    J Neurol. 2022;269:1663-1669.
    PubMed     Abstract available

  58. XIE H, Shao Y, Du J, Song Y, et al
    Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2022;269:1641-1650.
    PubMed     Abstract available

  59. NISSEN MS, Orvik MS, Nilsson AC, Ryding M, et al
    NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study.
    J Neurol. 2022;269:1618-1630.
    PubMed     Abstract available

  60. CACCIAGUERRA L, Storelli L, Radaelli M, Mesaros S, et al
    Application of deep-learning to the seronegative side of the NMO spectrum.
    J Neurol. 2022;269:1546-1556.
    PubMed     Abstract available

  61. HU J, Sun C, Lu J, Zhao C, et al
    Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    J Neurol. 2022;269:1250-1263.
    PubMed     Abstract available

  62. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
    PubMed     Abstract available

    February 2022
  63. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.

  64. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
    Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
    J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
    PubMed     Abstract available

  65. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
    Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
    PubMed     Abstract available

  66. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
    The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
    J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
    PubMed     Abstract available

  67. SOULAGES A, Sibon I, Vallat JM, Ellie E, et al
    Neurologic manifestations of giant cell arteritis.
    J Neurol. 2022 Feb 6. pii: 10.1007/s00415-022-10991.
    PubMed     Abstract available

  68. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
    Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
    PubMed     Abstract available

  69. ISMAIL II, Salama S
    Association of CNS demyelination and COVID-19 infection: an updated systematic review.
    J Neurol. 2022;269:541-576.
    PubMed     Abstract available

  70. PATZIG M, Forbrig R, Kupper C, Eren O, et al
    Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings.
    J Neurol. 2022;269:982-996.
    PubMed     Abstract available

  71. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
    NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
    J Neurol. 2022;269:836-845.
    PubMed     Abstract available

  72. SPINA E, Doneddu PE, Liberatore G, Cocito D, et al
    Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP.
    J Neurol. 2022;269:907-912.
    PubMed     Abstract available

  73. BUS SRM, Broers MC, Lucke IM, Bunschoten C, et al
    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
    J Neurol. 2022;269:945-955.
    PubMed     Abstract available

  74. LANDI D, Signori A, Cellerino M, Fenu G, et al
    What happens after fingolimod discontinuation? A multicentre real-life experience.
    J Neurol. 2022;269:796-804.
    PubMed     Abstract available

    January 2022
  75. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
    Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
    J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
    PubMed     Abstract available

  76. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
    Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
    J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
    PubMed     Abstract available

  77. GADOTH A, Segal Y, Paran Y, Aizenstein O, et al
    The importance of tissue-based assay in the diagnosis of autoimmune encephalitis.
    J Neurol. 2022 Jan 25. pii: 10.1007/s00415-022-10973.
    PubMed     Abstract available

  78. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
    Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
    PubMed     Abstract available

  79. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
    Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
    J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.

  80. MORANO A, Cerulli Irelli E, Fanella M, Orlando B, et al
    Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-022-10959.
    PubMed     Abstract available

  81. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
    PubMed     Abstract available

  82. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
    Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
    PubMed     Abstract available

  83. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
    Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
    PubMed     Abstract available

  84. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
    PubMed     Abstract available

  85. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
    PubMed     Abstract available

  86. THOMAS R, Wynford-Thomas R, Robertson NP
    Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.

  87. TALAEI M, Robertson NP
    Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy.
    J Neurol. 2022;269:534-536.

  88. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
    FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
    J Neurol. 2022;269:461-467.
    PubMed     Abstract available

  89. XU J, Guo Y, Li J, Lv X, et al
    Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:389-398.
    PubMed     Abstract available

  90. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
    Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
    J Neurol. 2022;269:49-54.

  91. DE LOTT LB, Bennett JL, Costello F
    The changing landscape of optic neuritis: a narrative review.
    J Neurol. 2022;269:111-124.
    PubMed     Abstract available

    December 2021
  92. LEGUY S, Le Page E, Drapier S
    Elderly onset neuromyelitis optica spectrum disorder: a case report.
    J Neurol. 2021;268:4897-4898.

  93. SRIWASTAVA S, Tandon M, Podury S, Prasad A, et al
    COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
    J Neurol. 2021;268:4448-4478.
    PubMed     Abstract available

  94. KONIG N, Stetefeld HR, Dohmen C, Mergenthaler P, et al
    MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.
    J Neurol. 2021;268:4824-4833.
    PubMed     Abstract available

    Paraneoplastic disorders of the nervous system.
    J Neurol. 2021;268:4899-4907.
    PubMed     Abstract available

    COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.
    J Neurol. 2021;268:4479-4482.

  97. SIRITHO S, Nopsopon T, Pongpirul K
    Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
    J Neurol. 2021;268:4549-4562.
    PubMed     Abstract available

  98. HOLMOY T, Hoglund RA, Illes Z, Myhr KM, et al
    Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    J Neurol. 2021;268:4522-4536.
    PubMed     Abstract available

    November 2021
  99. KAMBADJA B, Marion H, Cousyn L, Mezouar N, et al
    When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
    J Neurol. 2021 Nov 23. pii: 10.1007/s00415-021-10894.
    PubMed     Abstract available

  100. ANDERSEN LK, Jakobsson AS, Revsbech KL, Vissing J, et al
    Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
    J Neurol. 2021 Nov 21. pii: 10.1007/s00415-021-10902.
    PubMed     Abstract available

  101. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.

  102. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10893.
    PubMed     Abstract available

  103. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
    Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
    PubMed     Abstract available

  104. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10891.
    PubMed     Abstract available

  105. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2021 Nov 15. pii: 10.1007/s00415-021-10896.

  106. MCHATTIE AW, Coebergh J, Khan F, Morgante F, et al
    Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19.
    J Neurol. 2021;268:3995-3997.

    October 2021
  107. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    PubMed     Abstract available

  108. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    PubMed     Abstract available

  109. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
    Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
    PubMed     Abstract available

  110. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    PubMed     Abstract available

  111. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    PubMed     Abstract available

  112. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    PubMed     Abstract available

  113. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.

  114. FUKAMI Y, Iijima M, Koike H, Yamada S, et al
    Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
    J Neurol. 2021;268:3835-3844.
    PubMed     Abstract available

  115. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    PubMed     Abstract available

  116. QUEROL L, Crabtree M, Herepath M, Priedane E, et al
    Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2021;268:3706-3716.
    PubMed     Abstract available

  117. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    PubMed     Abstract available

    September 2021
  118. AHMED A, Kok ZQ, Coles A, Scoffings DJ, et al
    Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.
    J Neurol. 2021 Sep 29. pii: 10.1007/s00415-021-10802.

  119. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    PubMed     Abstract available

  120. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    PubMed     Abstract available

  121. BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
    Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
    PubMed     Abstract available

    Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
    J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.

  123. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    PubMed     Abstract available

  124. HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
    Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    J Neurol. 2021;268:3125-3128.
    PubMed     Abstract available

  125. VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
    COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:3129-3131.

    August 2021
  126. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    PubMed     Abstract available

  127. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    PubMed     Abstract available

  128. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    PubMed     Abstract available

  129. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    PubMed     Abstract available

  130. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    PubMed     Abstract available

  131. FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
    Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
    J Neurol. 2021;268:3011-3019.
    PubMed     Abstract available

  132. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    PubMed     Abstract available

  133. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    PubMed     Abstract available

  134. WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
    Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
    J Neurol. 2021;268:2700-2702.

    July 2021
  135. O SULLIVAN C, Zach F, Moser T, Pilz G, et al
    Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
    J Neurol. 2021 Jul 24. pii: 10.1007/s00415-021-10707.

  136. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    PubMed     Abstract available

  137. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    PubMed     Abstract available

  138. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.

  139. STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
    Sneddon syndrome: a comprehensive clinical review of 53 patients.
    J Neurol. 2021;268:2450-2457.
    PubMed     Abstract available

  140. MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
    A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
    J Neurol. 2021;268:2327-2330.
    PubMed     Abstract available

    June 2021
  141. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed     Abstract available

  142. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.

  143. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.

  144. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed     Abstract available

  145. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    PubMed     Abstract available

  146. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.

  147. KIM SH, Baek SH, Lee SU, Yu S, et al
    Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
    J Neurol. 2021;268:2263-2266.

  148. DAO LM, Machule ML, Bacher P, Hoffmann J, et al
    Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
    J Neurol. 2021;268:2123-2131.
    PubMed     Abstract available

  149. LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
    Bickerstaff encephalitis after COVID-19.
    J Neurol. 2021;268:2035-2037.

    May 2021
  150. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed     Abstract available

  151. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed     Abstract available

  152. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    PubMed     Abstract available

  153. KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
    Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.

  154. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    PubMed     Abstract available

  155. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    PubMed     Abstract available

  156. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    PubMed     Abstract available

  157. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    PubMed     Abstract available

  158. THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
    Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
    J Neurol. 2021;268:1818-1826.
    PubMed     Abstract available

    April 2021
  159. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    PubMed     Abstract available

  160. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    PubMed     Abstract available

  161. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    PubMed     Abstract available

  162. WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
    Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
    PubMed     Abstract available

  163. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    PubMed     Abstract available

  164. ZEIDAN S, Maillart E, Louapre C, Roux T, et al
    COVID-19 infection in NMO/SD patients: a French survey.
    J Neurol. 2021;268:1188-1190.

  165. URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
    Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
    J Neurol. 2021;268:1536-1539.

  166. KAPOOR M, Keh R, Compton L, Morrow S, et al
    Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    J Neurol. 2021;268:1485-1490.
    PubMed     Abstract available

  167. NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
    Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
    J Neurol. 2021;268:1419-1433.
    PubMed     Abstract available

  168. CHAUDHARY UJ, Rajabally YA
    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:1366-1373.
    PubMed     Abstract available

    March 2021
  169. MATHEY G, Pische G, Soudant M, Pittion-Vouyovitch S, et al
    Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.
    J Neurol. 2021 Mar 31. pii: 10.1007/s00415-021-10501.
    PubMed     Abstract available

  170. PINTER D, Kober SE, Fruhwirth V, Berger L, et al
    MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study.
    J Neurol. 2021 Mar 30. pii: 10.1007/s00415-021-10530.
    PubMed     Abstract available

  171. OZAWA Y, Uzawa A, Yasuda M, Kojima Y, et al
    Long-term outcomes and prognostic factors in generalized myasthenia gravis.
    J Neurol. 2021 Mar 27. pii: 10.1007/s00415-021-10520.
    PubMed     Abstract available

  172. SVACINA MKR, Kohle F, Sprenger A, Lehmann HC, et al
    Could symptom overlap of COVID-19 and Guillain-Barre syndrome mask an epidemiological association?
    J Neurol. 2021 Mar 17. pii: 10.1007/s00415-021-10515.

  173. HJAERESEN S, Sejbaek T, Axelsson M, Vinslov-Jensen H, et al
    The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis.
    J Neurol. 2021 Mar 4. pii: 10.1007/s00415-021-10489.
    PubMed     Abstract available

  174. RATH J, Zulehner G, Schober B, Grisold A, et al
    Cerebrospinal fluid analysis in Guillain-Barre syndrome: value of albumin quotients.
    J Neurol. 2021 Mar 2. pii: 10.1007/s00415-021-10479.
    PubMed     Abstract available

  175. VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
    Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
    J Neurol. 2021;268:978-988.
    PubMed     Abstract available

  176. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
    J Neurol. 2021;268:879-890.
    PubMed     Abstract available

    February 2021
  177. GOUDOT M, Frismand S, Hopes L, Verger A, et al
    Recurrent seizures of autoimmune origin: emerging phenotypes.
    J Neurol. 2021 Feb 27. pii: 10.1007/s00415-021-10457.
    PubMed     Abstract available

  178. TOLEDANO-ILLAN C, Esparragosa Vazquez I, Zelaya Huerta MV, Rosales Castillo JJ, et al
    Autoimmune glial fibrillary acidic protein astrocytopathy: case report of a treatable cause of rapidly progressive dementia.
    J Neurol. 2021 Feb 26. pii: 10.1007/s00415-021-10484.

  179. BUCELLO S, Annovazzi P, Ragonese P, Altieri M, et al
    Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    J Neurol. 2021 Feb 22. pii: 10.1007/s00415-021-10455.
    PubMed     Abstract available

  180. WALZL D, Solomon AJ, Stone J
    Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.
    J Neurol. 2021 Feb 21. pii: 10.1007/s00415-021-10436.
    PubMed     Abstract available

  181. CAPONE F, Ferraro E, Motolese F, Di Lazzaro V, et al
    COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10446.

  182. FILIPPI M, Capra R, Centonze D, Gasperini C, et al
    Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10466.

  183. JAKIMOVSKI D, Benedict RHB, Weinstock-Guttman B, Ozel O, et al
    Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?
    J Neurol. 2021 Feb 15. pii: 10.1007/s00415-021-10437.
    PubMed     Abstract available

  184. YOO JS, Kim YS, Kim HY, Kwon HS, et al
    Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
    J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
    PubMed     Abstract available

  185. MUNIZ-CASTRILLO S, Vogrig A, Montagnac C, Joubert B, et al
    Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study.
    J Neurol. 2021 Feb 5. pii: 10.1007/s00415-021-10424.
    PubMed     Abstract available

  186. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
    The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.
    J Neurol. 2021 Feb 1. pii: 10.1007/s00415-021-10400.
    PubMed     Abstract available

  187. MARTIN T, Duke S, Kumar V, Fadhil A, et al
    NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
    J Neurol. 2021;268:714-716.

  188. SCHROTER N, Weiller C, Rauer S, Waller CF, et al
    Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
    J Neurol. 2021;268:709-711.

  189. OKADA K, Seki M, Yaguchi H, Sakuta K, et al
    Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
    J Neurol. 2021;268:680-688.
    PubMed     Abstract available

  190. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    PubMed     Abstract available

    January 2021
  191. JORDAN B, Uer O, Buchholz T, Spens A, et al
    Physical fatigability and muscle pain in patients with Hashimoto thyroiditis.
    J Neurol. 2021 Jan 28. pii: 10.1007/s00415-020-10394.
    PubMed     Abstract available

  192. LUCCHINI M, Prosperini L, Buscarinu MC, Centonze D, et al
    Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    J Neurol. 2021 Jan 26. pii: 10.1007/s00415-021-10412.
    PubMed     Abstract available

  193. HARES K, Kemp K, Loveless S, Rice CM, et al
    KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.
    J Neurol. 2021 Jan 23. pii: 10.1007/s00415-020-10373.
    PubMed     Abstract available

  194. BOREMALM M, Sundstrom P, Salzer J
    Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10399.
    PubMed     Abstract available

  195. FAN Q, Hu Y, Wang X, Zhao B, et al
    Guillain-Barre syndrome in patients treated with immune checkpoint inhibitors.
    J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10404.
    PubMed     Abstract available

  196. CHISARI CG, Sgarlata E, Arena S, Toscano S, et al
    Rituximab for the treatment of multiple sclerosis: a review.
    J Neurol. 2021 Jan 8. pii: 10.1007/s00415-020-10362.
    PubMed     Abstract available

  197. KEVER A, Buyukturkoglu K, Riley CS, De Jager PL, et al
    Social support is linked to mental health, quality of life, and motor function in multiple sclerosis.
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10330.
    PubMed     Abstract available

  198. GELIBTER S, Pisa M, Croese T, Dalla Costa G, et al
    Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10322.
    PubMed     Abstract available

  199. ZHUO Z, Li Y, Duan Y, Cao G, et al
    Subtyping relapsing-remitting multiple sclerosis using structural MRI.
    J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10376.
    PubMed     Abstract available

  200. MONTE G, Spagni G, Damato V, Iorio R, et al
    Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
    J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10342.
    PubMed     Abstract available

  201. WOO MS, Steins D, Haussler V, Kohsar M, et al
    Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
    J Neurol. 2021;268:5-7.

  202. STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
    Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
    J Neurol. 2021;268:367-376.
    PubMed     Abstract available

  203. KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
    Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
    J Neurol. 2021;268:265-275.
    PubMed     Abstract available

    December 2020
  204. NEMA E, Kalina A, Nikolai T, Vyhnalek M, et al
    Correction to: Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Dec 30. pii: 10.1007/s00415-020-10294.

  205. NEUSS F, von Podewils F, Wang ZI, Susse M, et al
    Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy.
    J Neurol. 2020 Dec 15. pii: 10.1007/s00415-020-10346.
    PubMed     Abstract available

  206. MANTERO V, Rigamonti A, Basilico P, Crespi M, et al
    Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
    J Neurol. 2020;267:3465-3466.

  207. ZACHARIADIS A, Tulbu A, Strambo D, Dumoulin A, et al
    Transverse myelitis related to COVID-19 infection.
    J Neurol. 2020;267:3459-3461.

    November 2020
  208. PREZIOSA P, Rocca MA, Nozzolillo A, Moiola L, et al
    COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    J Neurol. 2020 Nov 20. pii: 10.1007/s00415-020-10309.

  209. BRACAGLIA M, Naldi I, Govoni A, Brillanti Ventura D, et al
    Acute inflammatory demyelinating polyneuritis in association with an asymptomatic infection by SARS-CoV-2.
    J Neurol. 2020;267:3166-3168.

    October 2020
  210. SIMONSEN CS, Flemmen HO, Broch L, Brunborg C, et al
    The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.
    J Neurol. 2020 Oct 22. pii: 10.1007/s00415-020-10279.
    PubMed     Abstract available

  211. ZECCA C, Disanto G, Sacco R, MacLachlan S, et al
    Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
    J Neurol. 2020 Oct 21. pii: 10.1007/s00415-020-10170.
    PubMed     Abstract available

  212. ARNETH B
    Contributions of T cells in multiple sclerosis: what do we currently know?
    J Neurol. 2020 Oct 20. pii: 10.1007/s00415-020-10275.
    PubMed     Abstract available

  213. LOTAN I, Hellmann MA, Wilf-Yarkoni A, Steiner I, et al
    Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.
    J Neurol. 2020 Oct 16. pii: 10.1007/s00415-020-10264.
    PubMed     Abstract available

  214. DOIG D, McNamara C, Mewasingh L, Beri S, et al
    Autoimmune cortical encephalitis in two children with anti-myelin oligodendrocyte glycoprotein (MOG) antibody.
    J Neurol. 2020 Oct 14. pii: 10.1007/s00415-020-10260.
    PubMed     Abstract available

  215. SRIWASTAVA S, Tandon M, Kataria S, Daimee M, et al
    New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.
    J Neurol. 2020 Oct 12. pii: 10.1007/s00415-020-10263.
    PubMed     Abstract available

  216. WILLIS MD, Robertson NP
    Multiple sclerosis: early indicators of disease and assessing future risk.
    J Neurol. 2020 Oct 8. pii: 10.1007/s00415-020-10239.

  217. PARSONS T, Banks S, Bae C, Gelber J, et al
    COVID-19-associated acute disseminated encephalomyelitis (ADEM).
    J Neurol. 2020;267:2799-2802.
    PubMed     Abstract available

    September 2020
  218. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Sep 24. pii: 10.1007/s00415-020-10226.
    PubMed     Abstract available

  219. MONSCHEIN T, Salhofer-Polanyi S, Altmann P, Zrzavy T, et al
    Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.
    J Neurol. 2020 Sep 14. pii: 10.1007/s00415-020-10074.
    PubMed     Abstract available

  220. LEJEUNE F, Chatton A, Laplaud DA, Le Page E, et al
    SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.
    J Neurol. 2020 Sep 9. pii: 10.1007/s00415-020-10154.
    PubMed     Abstract available

  221. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.
    J Neurol. 2020 Sep 3. pii: 10.1007/s00415-020-10194.
    PubMed     Abstract available

  222. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis.
    J Neurol. 2020 Sep 2. pii: 10.1007/s00415-020-10195.
    PubMed     Abstract available

  223. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms.
    J Neurol. 2020 Sep 2. pii: 10.1007/s00415-020-10192.
    PubMed     Abstract available

  224. FERNANDEZ-DOMINGUEZ J, Ameijide-Sanluis E, Garcia-Cabo C, Garcia-Rodriguez R, et al
    Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19).
    J Neurol. 2020;267:2495-2496.

    August 2020
  225. MANTERO V, Baroncini D, Balgera R, Guaschino C, et al
    Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
    J Neurol. 2020 Aug 31. pii: 10.1007/s00415-020-10196.

  226. ZHANG J, Chen MJ, Zhao GX, Li HF, et al
    Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.
    J Neurol. 2020 Aug 29. pii: 10.1007/s00415-020-10184.
    PubMed     Abstract available

  227. ABU-RUMEILEH S, Abdelhak A, Foschi M, Tumani H, et al
    Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.
    J Neurol. 2020 Aug 25. pii: 10.1007/s00415-020-10124.
    PubMed     Abstract available

  228. CHIARAVALLOTI ND, Amato MP, Brichetto G, Chataway J, et al
    The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis.
    J Neurol. 2020 Aug 19. pii: 10.1007/s00415-020-10160.
    PubMed     Abstract available

  229. VICINI R, Brugger D, Abegg M, Salmen A, et al
    Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis.
    J Neurol. 2020 Aug 12. pii: 10.1007/s00415-020-10097.
    PubMed     Abstract available

  230. PELEA T, Reuter U, Schmidt C, Laubinger R, et al
    SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neurol. 2020 Aug 8. pii: 10.1007/s00415-020-10133.
    PubMed     Abstract available

  231. ASHTON K, Fuchs TA, Oship D, Zivadinov R, et al
    Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption.
    J Neurol. 2020 Aug 4. pii: 10.1007/s00415-020-10110.
    PubMed     Abstract available

  232. MARINI A, Vogrig A, Bax F, Pellitteri G, et al
    Reply to "GuillainBarre syndrome in the COVID19 era another occasional cluster?": Insights from two distinct clusters of Guillain-Barre syndrome detected in Europe in the COVID-19 era.
    J Neurol. 2020 Aug 4. pii: 10.1007/s00415-020-10006.

  233. MUNZ M, Wessendorf S, Koretsis G, Tewald F, et al
    Acute transverse myelitis after COVID-19 pneumonia.
    J Neurol. 2020;267:2196-2197.

    July 2020
  234. YUAN S, Xiong Y, Larsson SC
    An atlas on risk factors for multiple sclerosis: a Mendelian randomization study.
    J Neurol. 2020 Jul 29. pii: 10.1007/s00415-020-10119.
    PubMed     Abstract available

  235. ACHIRON A, Ben-David A, Gurevich M, Magalashvili D, et al
    Parity and disability progression in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10093.
    PubMed     Abstract available

  236. CAPUANO R, Altieri M, Bisecco A, d'Ambrosio A, et al
    Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10099.
    PubMed     Abstract available

  237. HAUER L, Perneczky J, Sellner J
    A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.
    J Neurol. 2020 Jul 27. pii: 10.1007/s00415-020-10107.
    PubMed     Abstract available

  238. EVA N, Adam K, Tomas N, Martin V, et al
    Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Jul 22. pii: 10.1007/s00415-020-10079.
    PubMed     Abstract available

  239. KALRON A, Menascu S, Hoffmann C, Achiron A, et al
    The importance of physical activity to preserve hippocampal volume in people with multiple sclerosis: a structural MRI study.
    J Neurol. 2020 Jul 22. pii: 10.1007/s00415-020-10085.
    PubMed     Abstract available

  240. LI V, Panicker JN, Haslam C, Chataway J, et al
    Use of a symptom-based questionnaire to screen for the presence of significant voiding dysfunction in patients with multiple sclerosis and lower urinary tract symptoms: a pilot study.
    J Neurol. 2020 Jul 16. pii: 10.1007/s00415-020-10068.
    PubMed     Abstract available

  241. MATEEN FJ, Rezaei S, Alakel N, Gazdag B, et al
    Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
    J Neurol. 2020 Jul 7. pii: 10.1007/s00415-020-10045.
    PubMed     Abstract available

  242. DE SITTER A, Verhoeven T, Burggraaff J, Liu Y, et al
    Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort.
    J Neurol. 2020 Jul 3. pii: 10.1007/s00415-020-10023.
    PubMed     Abstract available

  243. KAMINSKY AL, Omorou AY, Soudant M, Pittion-Vouyovitch S, et al
    Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.
    J Neurol. 2020 Jul 2. pii: 10.1007/s00415-020-10029.
    PubMed     Abstract available

  244. RICCITELLI GC, Pagani E, Meani A, Valsasina P, et al
    Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study.
    J Neurol. 2020 Jul 2. pii: 10.1007/s00415-020-10025.
    PubMed     Abstract available

  245. PFEFFERKORN T, Dabitz R, von Wernitz-Keibel T, Aufenanger J, et al
    Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19.
    J Neurol. 2020;267:1883-1884.

  246. BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
    Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    J Neurol. 2020;267:2101-2114.
    PubMed     Abstract available

  247. MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
    Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
    J Neurol. 2020;267:1906-1911.
    PubMed     Abstract available

    June 2020
    Axonal degeneration in Guillain-Barre syndrome: a reappraisal.
    J Neurol. 2020 Jun 30. pii: 10.1007/s00415-020-10034.
    PubMed     Abstract available

  249. MANTERO V, Abate L, Basilico P, Balgera R, et al
    COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
    J Neurol. 2020 Jun 25. pii: 10.1007/s00415-020-10015.

  250. TATU L, Nono S, Gracio S, Kocer S, et al
    Guillain-Barre syndrome in the COVID-19 era: another occasional cluster?
    J Neurol. 2020 Jun 23. pii: 10.1007/s00415-020-10005.

  251. VAN FAALS NL, Dekker I, Balk LJ, Moraal B, et al
    Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance.
    J Neurol. 2020 Jun 20. pii: 10.1007/s00415-020-09991.
    PubMed     Abstract available

  252. KOLANKO M, Win Z, Patel N, Malik O, et al
    Using amyloid PET imaging to diagnose Alzheimer's disease in patients with multiple sclerosis.
    J Neurol. 2020 Jun 18. pii: 10.1007/s00415-020-09969.
    PubMed     Abstract available

  253. GRANBERG T, Moridi T, Brand JS, Neumann S, et al
    Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis.
    J Neurol. 2020 Jun 13. pii: 10.1007/s00415-020-09971.
    PubMed     Abstract available

  254. VANDEBERGH M, Goris A
    Smoking and multiple sclerosis risk: a Mendelian randomization study.
    J Neurol. 2020 Jun 11. pii: 10.1007/s00415-020-09980.
    PubMed     Abstract available

  255. LEHMANN AI, Rodgers S, Kamm CP, Mettler M, et al
    Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study.
    J Neurol. 2020 Jun 11. pii: 10.1007/s00415-020-09973.
    PubMed     Abstract available

  256. FERRAZZANO G, Crisafulli SG, Baione V, Tartaglia M, et al
    Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.
    J Neurol. 2020 Jun 5. pii: 10.1007/s00415-020-09964.
    PubMed     Abstract available

  257. WELLER D, Filli L, Meyer C, Lorincz L, et al
    Impaired speed-dependent modulation of the gait pattern in multiple sclerosis.
    J Neurol. 2020 Jun 4. pii: 10.1007/s00415-020-09965.
    PubMed     Abstract available

  258. MAGHZI AH, Houtchens MK, Preziosa P, Ionete C, et al
    COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    J Neurol. 2020 Jun 3. pii: 10.1007/s00415-020-09944.
    PubMed     Abstract available

  259. PATTI F, Zimatore GB, Brescia Morra V, Aguglia U, et al
    Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    J Neurol. 2020;267:1812-1823.
    PubMed     Abstract available

  260. MIAO A, Liu Q, Li Z, Liu W, et al
    Altered cerebral blood flow in patients with anti-NMDAR encephalitis.
    J Neurol. 2020;267:1760-1773.
    PubMed     Abstract available

  261. CAROTENUTO A, Costabile T, De Lucia M, Moccia M, et al
    Predictors of Nabiximols (Sativex((R))) discontinuation over long-term follow-up: a real-life study.
    J Neurol. 2020;267:1737-1743.
    PubMed     Abstract available

  262. LOOS J, Pfeuffer S, Pape K, Ruck T, et al
    MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
    J Neurol. 2020;267:1632-1642.
    PubMed     Abstract available

    May 2020
  263. TOMASSINI V, Sinclair A, Sawlani V, Overell J, et al
    Diagnosis and management of multiple sclerosis: MRI in clinical practice.
    J Neurol. 2020 May 29. pii: 10.1007/s00415-020-09930.
    PubMed     Abstract available

  264. ANGELINI L, Hodgkinson W, Smith C, Dodd JM, et al
    Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09928.
    PubMed     Abstract available

  265. SIVAKOLUNDU DK, West KL, Zuppichini MD, Wilson A, et al
    BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non-specific white matter disease: a three-dimensional approach.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09923.
    PubMed     Abstract available

  266. MOHN N, Saker F, Bonda V, Respondek G, et al
    Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09921.

  267. RIVA N, Russo T, Falzone YM, Strollo M, et al
    Post-infectious Guillain-Barre syndrome related to SARS-CoV-2 infection: a case report.
    J Neurol. 2020 May 26. pii: 10.1007/s00415-020-09907.

  268. GOLD R, Radue EW, Giovannoni G, Selmaj K, et al
    Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
    J Neurol. 2020 May 25. pii: 10.1007/s00415-020-09835.
    PubMed     Abstract available

  269. WILLIAMS T, Zetterberg H, Chataway J
    Neurofilaments in progressive multiple sclerosis: a systematic review.
    J Neurol. 2020 May 23. pii: 10.1007/s00415-020-09917.
    PubMed     Abstract available

  270. MORRIS JK, Lopez-Leon S, Geissbuhler Y, Sabido M, et al
    A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.
    J Neurol. 2020 May 22. pii: 10.1007/s00415-020-09913.
    PubMed     Abstract available

  271. GIGLI GL, Bax F, Marini A, Pellitteri G, et al
    Guillain-Barre syndrome in the COVID-19 era: just an occasional cluster?
    J Neurol. 2020 May 19. pii: 10.1007/s00415-020-09911.

  272. TSANTES E, Curti E, Ganazzoli C, Puci F, et al
    The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?
    J Neurol. 2020 May 12. pii: 10.1007/s00415-020-09894.
    PubMed     Abstract available

  273. KIM JG, Lee SU, Lee CN, Yu SW, et al
    Bilateral vestibulopathy as an early manifestation of systemic lupus erythematosus.
    J Neurol. 2020 May 11. pii: 10.1007/s00415-020-09876.

  274. KOCH MW, Mostert J, Greenfield J, Liu WQ, et al
    Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent.
    J Neurol. 2020 May 9. pii: 10.1007/s00415-020-09895.
    PubMed     Abstract available

  275. DING J, Ren K, Wu J, Li H, et al
    Overlapping syndrome of MOG-IgG-associated disease and autoimmune GFAP astrocytopathy.
    J Neurol. 2020 May 7. pii: 10.1007/s00415-020-09869.
    PubMed     Abstract available

  276. COLOMBO C, Confalonieri P, Rovaris M, La Mantia L, et al
    The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis.
    J Neurol. 2020 May 2. pii: 10.1007/s00415-020-09864.
    PubMed     Abstract available

  277. BUKHARI W, Clarke L, O'Gorman C, Khalilidehkordi E, et al
    The clinical profile of NMOSD in Australia and New Zealand.
    J Neurol. 2020;267:1431-1443.
    PubMed     Abstract available

  278. MOLONEY PB, Hutchinson S, Heskin J, Mulcahy F, et al
    Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape.
    J Neurol. 2020;267:1348-1352.
    PubMed     Abstract available

  279. CARNERO CONTENTTI E, Daccach Marques V, Soto de Castillo I, Tkachuk V, et al
    Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    J Neurol. 2020;267:1260-1268.
    PubMed     Abstract available

  280. WENDEBOURG MJ, Nagy S, Derfuss T, Parmar K, et al
    Magnetic resonance imaging in immune-mediated myelopathies.
    J Neurol. 2020;267:1233-1244.
    PubMed     Abstract available

    April 2020
  281. CHEN MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, et al
    Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09853.
    PubMed     Abstract available

  282. SABIN J, Urtiaga S, Pilo B, Thuissard I, et al
    Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09848.
    PubMed     Abstract available

  283. MATEEN FJ, Vogel AC, Kaplan TB, Hotan GC, et al
    Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09845.
    PubMed     Abstract available

  284. PADRONI M, Mastrangelo V, Asioli GM, Pavolucci L, et al
    Guillain-Barre syndrome following COVID-19: new infection, old complication?
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09849.

  285. MISICKA E, Sept C, Briggs FBS
    Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09850.
    PubMed     Abstract available

  286. GIBSON LL, McKeever A, Cullen AE, Nicholson TR, et al
    Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis.
    J Neurol. 2020 Apr 18. pii: 10.1007/s00415-020-09825.
    PubMed     Abstract available

  287. WILLIS MD, Robertson NP
    Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
    J Neurol. 2020 Apr 17. pii: 10.1007/s00415-020-09822.

  288. MATTIOLI F, Bellomi F, Stampatori C, Mariotto S, et al
    Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients.
    J Neurol. 2020 Apr 15. pii: 10.1007/s00415-020-09832.
    PubMed     Abstract available

  289. TANG L, Huang Q, Qin Z, Tang X, et al
    Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.
    J Neurol. 2020 Apr 7. pii: 10.1007/s00415-020-09823.
    PubMed     Abstract available

  290. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    J Neurol. 2020 Apr 3. pii: 10.1007/s00415-020-09811.
    PubMed     Abstract available

  291. ZHANG W, Cui L, Zhang Y, Wang W, et al
    Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population.
    J Neurol. 2020;267:1197-1205.
    PubMed     Abstract available

  292. BOYKO M, Au KLK, Casault C, de Robles P, et al
    Systematic review of the clinical spectrum of CASPR2 antibody syndrome.
    J Neurol. 2020;267:1137-1146.
    PubMed     Abstract available

  293. SHI Z, Du Q, Chen H, Zhang Y, et al
    Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    J Neurol. 2020;267:913-924.
    PubMed     Abstract available

    March 2020
  294. CAROTENUTO A, Wilson H, Giordano B, Caminiti SP, et al
    Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.
    J Neurol. 2020 Mar 26. pii: 10.1007/s00415-020-09806.
    PubMed     Abstract available

  295. BERARDO A, Emmanuele V, Vargas W, Tanji K, et al
    Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6.
    J Neurol. 2020;267:823-829.
    PubMed     Abstract available

  296. GIANNOCCARO MP, Di Stasi V, Zanesini C, Donadio V, et al
    Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation.
    J Neurol. 2020;267:739-745.
    PubMed     Abstract available

  297. HAMAGUCHI M, Suzuki K, Fujita H, Uzuka T, et al
    Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review.
    J Neurol. 2020;267:731-738.
    PubMed     Abstract available

    February 2020
  298. TANG MH, Mathis S, Duffau P, Cazenave P, et al
    Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort.
    J Neurol. 2020;267:561-571.
    PubMed     Abstract available

  299. SCHEIBE F, Ostendorf L, Reincke SM, Pruss H, et al
    Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis.
    J Neurol. 2020;267:317-323.
    PubMed     Abstract available

    January 2020
  300. FREEDMAN MS, Brod S, Singer BA, Cohen BA, et al
    Clinical and MRI efficacy of sc IFN beta-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    J Neurol. 2020;267:64-75.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.